MiraLAX Generics Get FDA Reprieve Despite Bayer Objections

Law360 (April 20, 2018, 7:13 PM EDT) -- Sales of generic versions of popular constipation drug MiraLAX will be allowed for an extra six months, the U.S. Food and Drug Administration revealed Friday, rejecting opposition from Bayer AG and reversing the agency's own recent order requiring sales to end promptly.

In a letter released Friday, the FDA acceded to some requests from four companies — Breckenridge Pharmaceutical Inc., Nexgen Pharma Inc., Lannett Co. Inc. and Paddock Laboratories Inc. — that sell generic, prescription versions of Bayer's MiraLAX, or polyethylene glycol 3350.

The FDA on April 2 ordered a halt to sales by May 2, but extended that deadline to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!